Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2018 March;43(1) > Minerva Endocrinologica 2018 March;43(1):50-6

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  THE EVOLUTION OF IVF 

Minerva Endocrinologica 2018 March;43(1):50-6

DOI: 10.23736/S0391-1977.17.02638-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Ovarian hyperstimulation syndrome management strategies: where are we going?

Ashley M. ESKEW, Kenan R. OMURTAG

Department of Reproductive Endocrinology and Infertility, Washington University School of Medicine, St. Louis, MO, USA


PDF


Ovarian hyperstimulation syndrome (OHSS) is one of the most frequent, serious and potentially lethal iatrogenic complications of controlled ovarian stimulation. Despite extensive research, the exact pathogenesis of this syndrome remains less clear, but there appears to be a relationship of increased vascular permeability mediated by HCG and other downstream mediators. Adequate experience with ovulation induction therapy and identifying patients with known risk factors are essential in preventing OHSS. As this is a completely iatrogenic disease numerous strategies have been investigated to help decrease the risk of OHSS and their effects on pregnancy and live birth rate. What follows is a review of the common strategies apply today to minimize risk of OHSS in patients undergoing assisted reproductive technologies.


KEY WORDS: Ovarian hyperstimulation syndrome - Gonadotropins - Leuprolide

top of page